Nuclear factor erythroid 2-related factor 2 (NRF2) accumulation via CRL3 inhibition can contribute to cancer growth, resistance to chemotherapy and radiation, and poor prognosis for patients [32, 33]. This evidence concerns the gene IL31RA and cancer.